跳至主要内容
临床试验/TCTR20230603001
TCTR20230603001已完成3 期

Comparison of therapeutic effects between Limaprost alfadex and Gabapentin in cervical myelopathy patient: Randomized controlled trial

Rajavithi hospital0 个研究点目标入组 60 人开始时间: 2023年6月3日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20 Years 至 80 Years(—)
性别
All

入选标准

  • 1. 20-80 years old
  • 2. Patients who meet the diagnostic criteria in the following topics
  • a. Symptom : Neck pain or aching pain down the arm or have numbness Weakness in arms, hands, abnormal gait
  • b. physical examination : Intrinsic muscle weakness , Finger escape sign + , Grip and release + , lhermitte test +
  • c. An MRI or CT scan showed narrowing of the spinal canal in the neck. together with spinal cord compression
  • d. The diagnosis was confirmed by an Orthopedic spine surgeon.
  • The diagnosis relies on a, b and d together, with or without c.
  • 3. Cooperate consent to participate in the research project

排除标准

  • 1. History of allergy to gabapentin or Pregabalin
  • 2. History of allergies to NSAIDs, Opioids
  • 3. Peripheral nerve entrapment and other pathology such as Tandem stenosis.
  • 4. Take anti-platelet drugs (ASA), anticoagulant drugs
  • 5. Received NSAID and Gabapentin treatment within 1 week prior to study participation.
  • 6. History of end-stage chronic kidney disease
  • 7. History of heart failure, ischemic heart disease
  • 8. History of cirrhosis
  • 9. History of peptic ulcer disease
  • 10. History of all types of cancer
  • 11. Persons diagnosed with cervical spondylosis with severe symptoms requiring surgery

研究者

相似试验